Power calculations and placebo effect for future clinical trials in progressive supranuclear palsy (Q37621250)

21 August 2017

Power calculations and placebo effect for future clinical trials in progressive supranuclear palsy (English)

1 reference

21 August 2017

0 references

1 reference

Wolfgang H Oertel

1 reference

21 August 2017

Maria Stamelou

1 reference

21 August 2017

Jakob Schöpe

1 reference

21 August 2017

Stefan Wagenpfeil

1 reference

21 August 2017

Teodoro Del Ser

1 reference

21 August 2017

Jee Bang

1 reference

21 August 2017

Iryna Y Lobach

1 reference

21 August 2017

Phi Luong

1 reference

21 August 2017

Gesine Respondek

1 reference

21 August 2017

AdamL Boxer

1 reference

21 August 2017

Günter U Höglinger

1 reference

21 August 2017

AL-108-231 Investigators, Tauros Investigators, and MDS-Endorsed PSP Study Group

1 reference

21 August 2017

language of work or name

English

0 references

publication date

7 March 2016

1 reference

21 August 2017

1 reference

21 August 2017

1 reference

21 August 2017

1 reference

21 August 2017

742-747

1 reference

The placebo effect: From concepts to genes.

21 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5289149

Davunetide in patients with progressive supranuclear palsy: a randomised, double-blind, placebo-controlled phase 2/3 trial

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5289149

A longitudinal study of motor, oculomotor and cognitive function in progressive supranuclear palsy

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5289149

Rates of brain atrophy and clinical decline over 6 and 12-month intervals in PSP: determining sample size for treatment trials

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5289149

Disease severity and progression in progressive supranuclear palsy and multiple system atrophy: validation of the NNIPPS--Parkinson Plus Scale

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5289149

Placebo response in Parkinson's disease: comparisons among 11 trials covering medical and surgical interventions

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5289149

Expectation and dopamine release: mechanism of the placebo effect in Parkinson's disease

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5289149

The FAB: a Frontal Assessment Battery at bedside.

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5289149

Natural history of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome) and clinical predictors of survival: a clinicopathological study

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5289149

Development and validation of a geriatric depression screening scale: a preliminary report

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5289149

The clinical features and natural history of the Steele-Richardson-Olszewski syndrome (progressive supranuclear palsy).

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5289149

The frontal assessment battery is not useful to discriminate progressive supranuclear palsy from frontotemporal dementias.

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5289149

The phenotypic spectrum of progressive supranuclear palsy: a retrospective multicenter study of 100 definite cases

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5289149

Clinical trials: past, current, and future for atypical Parkinsonian syndromes

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5289149

Rate of decline in progressive supranuclear palsy

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5289149

Reliability, validity, and clinical correlates of apathy in Parkinson's disease

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5289149

A phase 2 trial of the GSK-3 inhibitor tideglusib in progressive supranuclear palsy

25 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5289149

Tideglusib reduces progression of brain atrophy in progressive supranuclear palsy in a randomized trial.

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5289149

Short-term effects of coenzyme Q10 in progressive supranuclear palsy: a randomized, placebo-controlled trial

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5289149

A clinical rating scale for progressive supranuclear palsy

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5289149

Progressive supranuclear palsy: a survey of the disease course.

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5289149

Objective changes in motor function during placebo treatment in PD

1 September 2018

1 reference

12 December 2020

Natural history and clinical features of progressive supranuclear palsy: a clinical study

1 reference

12 December 2020

Natural history of progressive supranuclear palsy: a clinicopathologic study from a population of brain donors

1 reference

12 December 2020

Disease-Modifying Treatments for Progressive Supranuclear Palsy

1 reference

12 December 2020

Identifiers

DOI

10.1002/MDS.26580

1 reference

21 August 2017

1 reference

21 August 2017

PubMed publication ID

26948290

1 reference